AtriCure

ATRC

Market cap $1.76B

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2025 financial results on Wednesday, October 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, October 29, 2025, to discuss its third quarter 2025 financial results. Those interested.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced the launch of the cryoXT™ device, an innovative cryoablation technology used to help manage post-operative pain following amputation procedures. Each year, over 185,000 amputations occur in the U.S., with approximately 60%1 of patients experiencing residual.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2025 Wells Fargo Healthcare Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, September 3, 2025, at 3:45 p.m. Eastern Standard Time. Interested parties may a.

AtriCure (ATRC) Q2 Revenue Jumps 17%

AtriCure, Inc. (NASDAQ:ATRC ) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Angela L. Wirick - Chief Financial Officer Michael H.

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

AtriCure (ATRC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.17 per share a year ago.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2025 financial results. “Our stellar results reflect the power of innovation and the growing impact of our expanding portfolio, particularly in our AtriClip platform and cryoSPHERE device offerings. We're seeing increasing momentum as our new.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference. AtriCure's management is scheduled to present on Tuesday, August 12, 2025, at 2:30 p.m. Eastern Standard Time. Interested parties may access a live audio.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the completion of enrollment in the left atrial appendage exclusion for prophylactic stroke reduction (LeAAPS) clinical trial (NCT05478304). Initiated in January 2023, LeAAPS enrolled 6,500 patients across 137 centers globally. LeAAPS is a prospective, randomized, blinde.